Immunocore Holdings (IMCR) Cash & Equivalents (2019 - 2026)

Immunocore Holdings has disclosed Cash & Equivalents across 8 years of filings, most recently posting $452.7 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $452.7 million, down 5.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $452.7 million (down 5.07% YoY), and the FY2025 annual result was $467.7 million, up 2.63% from the prior year.
• Cash & Equivalents came in at $452.7 million for Q1 2026 at Immunocore Holdings, down from $467.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $832.8 million in Q1 2024 to a low of $390.0 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $476.8 million (2025), against an average of $504.3 million.
• Across the five-year window, Cash & Equivalents climbed 21.63% in 2022 and tumbled 42.74% in 2025, its largest moves.
• Immunocore Holdings' Cash & Equivalents stood at $390.0 million in 2022, then increased by 13.48% to $442.6 million in 2023, then advanced by 2.96% to $455.7 million in 2024, then rose by 2.63% to $467.7 million in 2025, then slipped by 3.21% to $452.7 million in 2026.
• The last three Cash & Equivalents figures came in at $452.7 million (Q1 2026), $467.7 million (Q4 2025), and $498.4 million (Q3 2025), per Business Quant data.